- Home
- UMAC vs ETON Comparison
UMAC vs ETON Comparison
Compare UMAC & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UMAC | ETON |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 520.2M | 411.9M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | UMAC | ETON |
|---|---|---|
| Price | $22.19 | $19.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $20.00 | ★ $31.00 |
| AVG Volume (30 Days) | ★ 2.7M | 294.8K |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,565,319.00 | ★ $39,011,000.00 |
| Revenue This Year | $134.64 | $107.23 |
| Revenue Next Year | $85.71 | $29.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $4.45 | $11.09 |
| 52 Week High | $20.25 | $23.00 |
Technical Indicators
Market Signals| Indicator | UMAC | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 77.34 | 66.47 |
| Support Level | $8.18 | $16.04 |
| Resistance Level | N/A | $20.01 |
| Average True Range (ATR) | 1.61 | 1.09 |
| MACD | 0.86 | 0.05 |
| Stochastic Oscillator | 87.28 | 75.56 |
Price Performance
Historical ComparisonAbout UMAC Unusual Machines Inc.
Unusual Machines Inc is engaged in serving the American drone industry by building and selling drone components.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.